Human poly- and cross-reactive anti-viral antibodies and their impact on protection and pathology

Immunologic Research

Volumn 53, Issue 1-3, 2012, Pages 148-161

  Warter, Lucile ^a   Appanna, Ramapraba ^a   Fink, Katja ^a  

^a AGENCY FOR SCIENCE   (Singapore)

Author keywords

Antibodies; B cells; Dengue; HCV; HIV; Influenza; Memory; Original antigenic sin; Plasmablasts; Viral infection

Indexed keywords

AUTOANTIBODY; CROSS REACTING ANTIBODY; DENGUE VACCINE; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; POLYREACTIVE ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ANTIBODY AFFINITY; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN ANTIBODY COMPLEX; ARTICLE; DENGUE; DENGUE VIRUS; DRUG DESIGN; GENOTYPE; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; IMMUNOPATHOLOGY; INFLUENZA; INFLUENZA VIRUS; MEMORY CELL; NONHUMAN; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; TISSUE SPECIFICITY; VIRUS IMMUNITY; VIRUS INFECTION; VIRUS NEUTRALIZATION; VIRUS STRAIN;

ACUTE DISEASE; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CHRONIC DISEASE; CROSS REACTIONS; DENGUE; DENGUE VACCINES; DENGUE VIRUS; HIV; HIV INFECTIONS; HUMANS; IMMUNITY, HUMORAL; IMMUNOLOGIC MEMORY;

EID: 84866740289     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-012-8268-8     Document Type: Article

References (126)

1. Avrameas S. Natural autoantibodies: from 'horror autotoxicus' to 'gnothi seauton'. Immunol Today. 1991;12(5):154-9. Epub 1991/05/01. PubMed PMID: 1715166.
2. Mouthon L, Nobrega A, Nicolas N, Kaveri SV, Barreau C, Coutinho A, et al. Invariance and restriction toward a limited set of self-antigens characterize neonatal IgM antibody repertoires and prevail in autoreactive repertoires of healthy adults. Proc Natl Acad Sci USA. 1995;92(9):3839-43. Epub 1995/04/25. PubMed PMID: 7731992; PubMed Central PMCID: PMC42057.
3. Briles DE, Nahm M, Schroer K, Davie J, Baker P, Kearney J, et al. Antiphosphocholine antibodies found in normal mouse serum are protective against intravenous infection with type 3 streptococcus pneumoniae. J Exp Med. 1981;153(3):694-705. Epub 1981/03/01. PubMed PMID: 7252411; PubMed Central PMCID: PMC2186108.
4. Jayasekera JP, Moseman EA, Carroll MC. Natural antibody and complement mediate neutralization of influenza virus in the absence of prior immunity. J Virol. 2007;81(7):3487-94. Epub 2007/01/05. doi:10.1128/JVI.02128-06. PubMed PMID: 17202212; PubMed Central PMCID: PMC1866020.
5. Ochsenbein AF, Fehr T, Lutz C, Suter M, Brombacher F, Hengartner H, et al. Control of early viral and bacterial distribution and disease by natural antibodies. Science. 1999; 286(5447):2156-9. Epub 1999/12/11. PubMed PMID: 10591 647.
6. Choi YS, Baumgarth N. Dual role for B-1a cells in immunity to influenza virus infection. J Exp Med. 2008;205(13):3053-64. Epub 2008/12/17. doi:10.1084/jem.20080979. PubMed PMID: 19075288; PubMed Central PMCID: PMC2605232.
7. Zola TA, Lysenko ES, Weiser JN. Natural antibody to conserved targets of Haemophilus influenzae limits colonization of the murine nasopharynx. Infect Immun. 2009;77(8):3458-65. Epub 2009/05/20. doi:10.1128/IAI.01564-08. PubMed PMID: 19451240; PubMed Central PMCID: PMC2715656.
8. Cohen IR, Norins LC. Natural human antibodies to gram-negative bacteria: immunoglobulins G, A, and M. Science. 1966;152(726):1257-9. Epub 1966/05/27. PubMed PMID: 5327 885.
9. Navin TR, Krug EC, Pearson RD. Effect of immunoglobulin M from normal human serum on Leishmania donovani promastigote agglutination, complement-mediated killing, and phagocytosis by human monocytes. Infect Immun. 1989;57(4): 1343-6. Epub 1989/04/01. PubMed PMID: 2925255; PubMed Central PMCID: PMC313275.
10. Takeuchi Y, Liong SH, Bieniasz PD, Jager U, Porter CD, Friedman T, et al. Sensitization of rhabdo-, lenti-, and spumaviruses to human serum by galactosyl(alpha1-3)galactosylation. J Virol. 1997;71(8):6174-8. Epub 1997/08/01. PubMed PMID: 9223512; PubMed Central PMCID: PMC191878.
11. Ehrenstein MR, Notley CA. The importance of natural IgM: scavenger, protector and regulator. Nat Rev Immunol. 2010; 10(11):778-86. Epub 2010/10/16. doi:10.1038/nri2849. PubMed PMID: 20948548.
12. Lutz HU, Bussolino F, Flepp R, Fasler S, Stammler P, Kazatchkine MD, et al. Naturally occurring anti-band-3 antibodies and complement together mediate phagocytosis of oxidatively stressed human erythrocytes. Proc Natl Acad Sci USA. 1987;84(21):7368-72. Epub 1987/11/01. PubMed PMID: 3313392; PubMed Central PMCID: PMC299297.
13. Bayry J, Lacroix-Desmazes S, Donkova-Petrini V, Carbonneil C, Misra N, Lepelletier Y, et al. Natural antibodies sustain differentiation and maturation of human dendritic cells. Proc Natl Acad Sci USA. 2004;101(39):14210-5. Epub 2004/09/24. doi:10.1073/pnas.0402183101. PubMed PMID: 15381781; PubMed Central PMCID: PMC521138.
14. Benckert J, Schmolka N, Kreschel C, Zoller MJ, Sturm A, Wiedenmann B, et al. The majority of intestinal IgA? and IgG? plasmablasts in the human gut are antigen-specific. The Journal of clinical investigation. 2011;121(5):1946-55. Epub 2011/04/15. doi:10.1172/JCI44447. PubMed PMID: 21490392; PubMed Central PMCID: PMC3083800.
15. Scheid JF, Mouquet H, Kofer J, Yurasov S, Nussenzweig MC, Wardemann H. Differential regulation of self-reactivity discriminates between IgG? human circulating memory B cells and bone marrow plasma cells. Proc Natl Acad Sci USA. 2011;108(44):18044-8. Epub 2011/10/26. doi:10.1073/pnas.1113395108. PubMed PMID: 22025722.
16. Tiller T, Meffre E, Yurasov S, Tsuiji M, Nussenzweig MC, Wardemann H. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J Immunol Methods. 2008;329(1-2): 112-24. Epub 2007/11/13. doi:10.1016/j.jim.2007.09.017. Pub- Med PMID: 17996249; PubMed Central PMCID: PMC2243222.
17. Tiller T, Tsuiji M, Yurasov S, Velinzon K, Nussenzweig MC, Wardemann H. Autoreactivity in human IgG? memory B cells. Immunity. 2007;26(2):205-13. Epub 2007/02/20. doi:10.1016/ j.immuni.2007.01.009. PubMed PMID: 17306569; PubMed Central PMCID: PMC1839941.
18. Ichiyoshi Y, Casali P. Analysis of the structural correlates for antibody polyreactivity by multiple reassortments of chimeric human immunoglobulin heavy and light chain V segments. J Exp Med. 1994;180(3):885-95. Epub 1994/09/01. PubMed PMID: 8064239; PubMed Central PMCID: PMC2191637.
19. Liao HX, Chen X, Munshaw S, Zhang R, Marshall DJ, Vandergrift N, et al. Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. J Exp Med. 2011;208(11):2237-49. Epub 2011/10/12. doi: 10.1084/jem.20110363. PubMed PMID: 21987658; PubMed Central PMCID: PMC3201211.
20. Zhou ZH, Zhang Y, Hu YF, Wahl LM, Cisar JO, Notkins AL. The broad antibacterial activity of the natural antibody repertoire is due to polyreactive antibodies. Cell Host Microbe. 2007;1(1):51-61. Epub 2007/11/17. doi:10.1016/j.chom.2007. 01.002. PubMed PMID: 18005681; PubMed Central PMCID: PMC2212603.
21. Ng YS, Wardemann H, Chelnis J, Cunningham-Rundles C, Meffre E. Bruton's tyrosine kinase is essential for human B cell tolerance. J Exp Med. 2004;200(7):927-34. Epub 2004/10/07. doi:10.1084/jem.20040920. PubMed PMID: 15466623; PubMed Central PMCID: PMC2213290.
22. Yurasov S, Wardemann H, Hammersen J, Tsuiji M, Meffre E, Pascual V, et al. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med. 2005;201(5):703-11. Epub 2005/03/02. doi:10.1084/jem.20042251. PubMed PMID: 15738055; PubMed Central PMCID: PMC2212839.
23. Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC. Predominant autoantibody production by early human B cell precursors. Science. 2003;301(5638): 1374-7. Epub 2003/08/16. doi:10.1126/science.1086907. Pub- Med PMID: 12920303.
24. Duty JA, Szodoray P, Zheng NY, Koelsch KA, Zhang Q, Swiatkowski M, et al. Functional anergy in a subpopulation of naive B cells from healthy humans that express autoreactive immunoglobulin receptors. J Exp Med. 2009;206(1):139-51. Epub 2008/12/24. doi:10.1084/jem.20080611. PubMed PMID: 19103878; PubMed Central PMCID: PMC2626668.
25. Eschbach C, Bach MP, Fidler I, Pelanda R, Kohler F, Rajewsky K, et al. Efficient generation of B lymphocytes by recognition of selfantigens. Eur J Immunol. 2011;41(8):2397-403. Epub 2011/05/24. doi:10.1002/eji.201041344. PubMed PMID: 21604259.
26. Kohler F, Hug E, Eschbach C, Meixlsperger S, Hobeika E, Kofer J, et al. Autoreactive B cell receptors mimic autonomous pre-B cell receptor signaling and induce proliferation of early B cells. Immunity. 2008;29(6):912-21. Epub 2008/12/17. doi: 10.1016/j.immuni.2008.10.013. PubMed PMID: 19084434.
27. Brezinschek HP, Brezinschek RI, Lipsky PE. Analysis of the heavy chain repertoire of human peripheral B cells using singlecell polymerase chain reaction. J Immunol. 1995;155(1):190-202. Epub 1995/07/01. PubMed PMID: 7602095.
28. Sui J, Hwang WC, Perez S, Wei G, Aird D, Chen LM, et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nature structural & molecular biology. 2009;16(3):265-73. Epub 2009/02/24. doi: 10.1038/nsmb.1566. PubMed PMID: 19234466; PubMed Central PMCID: PMC2692245.
29. Throsby M, Geuijen C, Goudsmit J, Bakker AQ, Korimbocus J, Kramer RA, et al. Isolation and characterization of human monoclonal antibodies from individuals infected with West Nile Virus. J Virol. 2006;80(14):6982-92. PubMed PMID: 16809304.
30. Ditzel HJ, Itoh K, Burton DR. Determinants of polyreactivity in a large panel of recombinant human antibodies from HIV-1 infection. J Immunol. 1996;157(2):739-49. Epub 1996/07/15. PubMed PMID: 8752924.
31. James LC, Roversi P, Tawfik DS. Antibody multispecificity mediated by conformational diversity. Science. 2003;299(5611): 1362-7. Epub 2003/03/01. doi:10.1126/science.1079731. Pub- Med PMID: 12610298.
32. Zimmermann J, Romesberg FE, Brooks CL, 3rd, Thorpe IF. Molecular description of flexibility in an antibody combining site. The journal of physical chemistry B. 2010;114(21):7359-70. Epub 2010/05/12. doi:10.1021/jp906421v. PubMed PMID: 20455589; PubMed Central PMCID: PMC2892760.
33. McMahon MJ, O'Kennedy R. Polyreactivity as an acquired artefact, rather than a physiologic property, of antibodies: evidence that monoreactive antibodies may gain the ability to bind to multiple antigens after exposure to low pH. J Immunol Methods. 2000;241(1-2):1-10. Epub 2000/08/01. PubMed PMID: 10915844.
34. Dimitrov JD, Ivanovska ND, Lacroix-Desmazes S, Doltchinkova VR, Kaveri SV, Vassilev TL. Ferrous ions and reactive oxygen species increase antigen-binding and anti-inflammatory activities of immunoglobulin G. J Biol Chem. 2006;281(1):439-46. Epub 2005/10/26. doi:10.1074/jbc.M509190200. PubMed PMID: 16246843.
35. Mihaylova NM, Dimitrov JD, Djoumerska-Alexieva IK, Vassilev TL. Inflammation-induced enhancement of IgG immunoreactivity. Inflammation research : official journal of the European Histamine Research Society [et al.]. 2008;57(1):1-3. Epub 2008/01/23. doi:10.1007/s00011-007-6213-4. PubMed PMID: 18209958.
36. Matsuda F, Ishii K, Bourvagnet P, Kuma K, Hayashida H, Miyata T, et al. The complete nucleotide sequence of the human immunoglobulin heavy chain variable region locus. J Exp Med. 1998;188(11):2151-62. Epub 1998/12/08. PubMed PMID: 9841928; PubMed Central PMCID: PMC2212390.
37. Berkowska MA, Driessen GJ, Bikos V, Grosserichter-Wagener C, Stamatopoulos K, Cerutti A, et al. Human memory B cells originate from three distinct germinal center-dependent and - independent maturation pathways. Blood. 2011;118(8):2150-8. Epub 2011/06/22. doi:10.1182/blood-2011-04-345579. PubMed PMID: 21690558.
38. Wrammert J, Smith K, Miller J, Langley WA, Kokko K, Larsen C, et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature. 2008;453(7195):667-71. Epub 2008/05/02. doi:10.1038/nature06890. PubMed PMID: 18449194; PubMed Central PMCID: PMC2515609.
39. Sukupolvi-Petty S, Austin SK, Purtha WE, Oliphant T, Nybakken GE, Schlesinger JJ, et al. Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol. 2007;81(23):12816-26. Epub 2007/09/21. doi:10.1128/ JVI.00432-07. PubMed PMID: 17881453; PubMed Central PMCID: PMC2169112.
40. Brien JD, Austin SK, Sukupolvi-Petty S, O'Brien KM, Johnson S, Fremont DH, et al. Genotype Specific Neutralization and Protection by Antibodies against Dengue Virus Type 3. J Virol. 2010. Epub 2010/08/13. doi:10.1128/JVI.01190-10. PubMed PMID: 20702644.
41. Davenport FM, Hennessy AV, Francis T, Jr. Epidemiologic and immunologic significance of age distribution of antibody to antigenic variants of influenza virus. J Exp Med. 1953;98(6): 641-56. Epub 1953/12/01. PubMed PMID: 13109114; PubMed Central PMCID: PMC2136340.
42. Gulati U, Kumari K, Wu W, Keitel WA, Air GM. Amount and avidity of serum antibodies against native glycoproteins and denatured virus after repeated influenza whole-virus vaccination. Vaccine. 2005;23(11):1414-25. Epub 2005/01/22. doi: 10.1016/j.vaccine.2004.08.053. PubMed PMID: 15661391.
43. Kim JH, Skountzou I, Compans R, Jacob J. Original antigenic sin responses to influenza viruses. J Immunol. 2009;183(5): 3294-301. Epub 2009/08/04. doi:10.4049/jimmunol.0900398. PubMed PMID: 19648276.
44. Halstead SB, Rojanasuphot S, Sangkawibha N. Original antigenic sin in dengue. Am J Trop Med Hyg. 1983;32(1):154-6. Epub 1983/01/01. PubMed PMID: 6824120.
45. Midgley CM, Bajwa-Joseph M, Vasanawathana S, Limpitikul W, Wills B, Flanagan A, et al. An in-depth analysis of original antigenic sin in dengue virus infection. J Virol. 2010;85(1):410-21. Epub 2010/10/29. doi:10.1128/JVI.01826-10. PubMed PMID: 20980526; PubMed Central PMCID: PMC3014204.
46. Mongkolsapaya J, Dejnirattisai W, Xu XN, Vasanawathana S, Tangthawornchaikul N, Chairunsri A, et al. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med. 2003;9(7):921-7. PubMed PMID: 12808447.
47. Halstead SB. Dengue. Lancet. 2007;370(9599):1644-52. Pub- Med PMID: 17993365.
48. Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli L, Quyen NT, et al. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe. 2010;8(3):271-83. Epub 2010/09/14. doi:10.1016/ j.chom.2010.08.007. PubMed PMID: 20833378.
49. Crill WD, Hughes HR, Delorey MJ, Chang GJ. Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens. PLoS One. 2009;4(4):e4991. Epub 2009/04/02. doi:10.1371/journal.pone. 0004991. PubMed PMID: 19337372; PubMed Central PMCID: PMC2659788.
50. Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, Limpitikul W, et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science. 2010; 328(5979):745-8. Epub 2010/05/08. doi:10.1126/science. 1185181. PubMed PMID: 20448183.
51. Lai CY, Tsai WY, Lin SR, Kao CL, Hu HP, King CC, et al. Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. J Virol. 2008;82(13):6631-43. Pub- Med PMID: 18448542.
52. Schieffelin JS, Costin JM, Nicholson CO, Orgeron NM, Fontaine KA, Isern S, et al. Neutralizing and non-neutralizing monoclonal antibodies against dengue virus E protein derived from a naturally infected patient. Virol J. 2010;7:28. Epub 2010/02/06. doi:10.1186/1743-422X-7-28. PubMed PMID: 20132551; PubMed Central PMCID: PMC2829534.
53. de Alwis R, Beltramello M, Messer WB, Sukupolvi-Petty S, Wahala WM, Kraus A, et al. In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. PLoS Negl Trop Dis. 2011;5(6):e1188. Epub 2011/06/30. doi:10.1371/journal.pntd.0001188. PubMed PMID: 21713020; PubMed Central PMCID: PMC3119640.
54. Mathew A, West K, Kalayanarooj S, Gibbons RV, Srikiatkhachorn A, Green S, et al. B-cell responses during primary and secondary dengue virus infections in humans. J Infect Dis. 2011;204(10):1514-22. Epub 2011/09/21. doi:10.1093/infdis/ jir607. PubMed PMID: 21930609.
55. Mikell I, Sather DN, Kalams SA, Altfeld M, Alter G, Stamatatos L. Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog. 2011;7(1):e1001251. Epub 2011/01/21. doi:10.1371/journal.ppat. 1001251. PubMed PMID: 21249232; PubMed Central PMCID: PMC3020924.
56. Stamatatos L, Morris L, Burton DR, Mascola JR. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nature medicine. 2009;15(8):866-70. Epub 2009/06/16. doi:10.1038/nm.1949. PubMed PMID: 19525964.
57. Deeks SG, Schweighardt B, Wrin T, Galovich J, Hoh R, Sinclair E, et al. Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses. J Virol. 2006;80(12):6155-64. Epub 2006/05/30. doi: 10.1128/JVI.00093-06. PubMed PMID: 16731954; PubMed Central PMCID: PMC1472617.
58. Sather DN, Armann J, Ching LK, Mavrantoni A, Sellhorn G, Caldwell Z, et al. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol. 2009;83(2):757-69. Epub 2008/11/07. doi:10.1128/JVI.02036-08. PubMed PMID: 18987148; PubMed Central PMCID: PMC2612355.
59. Euler Z, van Gils MJ, Bunnik EM, Phung P, Schweighardt B, Wrin T, et al. Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression. J Infect Dis. 2010;201(7):1045-53. Epub 2010/02/23. doi:10.1086/651144. PubMed PMID: 20170371.
60. Piantadosi A, Panteleeff D, Blish CA, Baeten JM, Jaoko W, McClelland RS, et al. Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression. J Virol. 2009;83(19):10269-74. Epub 2009/07/31. doi:10.1128/ JVI.01149-09. PubMed PMID: 19640996; PubMed Central PMCID: PMC2748011.
61. Doria-Rose NA, Klein RM, Daniels MG, O'Dell S, Nason M, Lapedes A, et al. Breadth of human immunodeficiency virusspecific neutralizing activity in sera: clustering analysis and association with clinical variables. J Virol. 2010;84(3):1631-6. Epub 2009/11/20. doi:10.1128/JVI.01482-09. PubMed PMID: 19923174; PubMed Central PMCID: PMC2812355.
62. Mondelli MU, Cerino A, Lisa A, Brambilla S, Segagni L, Cividini A, et al. Antibody responses to hepatitis C virus hypervariable region 1: evidence for cross-reactivity and immune-mediated sequence variation. Hepatology. 1999;30(2): 537-45. Epub 1999/07/27. doi:10.1002/hep.510300233. Pub- Med PMID: 10421665.
63. Osburn WO, Fisher BE, Dowd KA, Urban G, Liu L, Ray SC, et al. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology. 2010;138(1):315-24. Epub 2009/09/29. doi:10.1053/j.gastro. 2009.09.017. PubMed PMID: 19782080; PubMed Central PMCID: PMC2889495.
64. Halstead. Immunopathological parameters of togavirus disease syndromes. W S, editor. New York: Academic Press; 1980.
65. Kurane I EF. Immunopathogenesis of dengue virus infections. Gubler DJ KG, editor. Oxon, UK: CBA International; 1997.
66. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn S, et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis. 2000;181(1):2-9. Epub 1999/12/23. doi:10.1086/315215. PubMed PMID: 10608744.
67. Goncalvez AP, Engle RE, St Claire M, Purcell RH, Lai CJ. Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc Natl Acad Sci USA. 2007;104(22):9422-7. Epub 2007/05/23. doi:10.1073/pnas.0703498104. PubMed PMID: 17517625; PubMed Central PMCID: PMC1868655.
68. Guzman MG, Alvarez M, Rodriguez-Roche R, Bernardo L, Montes T, Vazquez S, et al. Neutralizing antibodies after infection with dengue 1 virus. Emerg Infect Dis. 2007;13(2): 282-6. Epub 2007/05/08. PubMed PMID: 17479892; PubMed Central PMCID: PMC2725871.
69. Halstead SB, Scanlon JE, Umpaivit P, Udomsakdi S. Dengue and chikungunya virus infection in man in Thailand, 1962-1964. IV. Epidemiologic studies in the Bangkok metropolitan area. Am J Trop Med Hyg. 1969;18(6):997-1021. Epub 1969/11/01. PubMed PMID: 4390977.
70. Libraty DH, Acosta LP, Tallo V, Segubre-Mercado E, Bautista A, Potts JA, et al. A prospective nested case-control study of Dengue in infants: rethinking and refining the antibody-dependent enhancement dengue hemorrhagic fever model. PLoS Med. 2009;6(10):e1000171. Epub 2009/10/28. doi:10.1371/journal. pmed.1000171. PubMed PMID: 19859541; PubMed Central PMCID: PMC2762316.
71. Schmidt AC. Response to dengue fever-the good, the bad, and the ugly? N Engl J Med. 2010;363(5):484-7. Epub 2010/09/08. doi:10.1056/NEJMcibr1005904. PubMed PMID: 20818870.
72. Guzman MG, Kouri GP, Bravo J, Soler M, Vazquez S, Morier L. Dengue hemorrhagic fever in Cuba, 1981: a retrospective seroepidemiologic study. Am J Trop Med Hyg. 1990;42(2):179-84. Epub 1990/02/01. PubMed PMID: 2316788.
73. Sullivan NJ. Antibody-mediated enhancement of viral disease. Curr Top Microbiol Immunol. 2001;260:145-69. Epub 2001/07/11. PubMed PMID: 11443872.
74. Rulli NE, Suhrbier A, Hueston L, Heise MT, Tupanceska D, Zaid A, et al. Ross River virus: molecular and cellular aspects of disease pathogenesis. Pharmacol Ther. 2005;107(3):329-42. Epub 2005/06/01. doi:10.1016/j.pharmthera. 2005.03.006. Pub- Med PMID: 15923040.
75. Klimstra WB, Williams JC, Ryman KD, Heidner HW. Targeting Sindbis virus-based vectors to Fc receptor-positive cell types. Virology. 2005;338(1):9-21. Epub 2005/06/01. doi:10.1016/ j.virol.2005.04.039. PubMed PMID: 15922395.
76. Rodenhuis-Zybert IA, van der Schaar HM, da Silva Voorham JM, van der Ende-Metselaar H, Lei HY, Wilschut J, et al. Immature dengue virus: a veiled pathogen? PLoS Pathog. 2010;6(1):e1000718. Epub 2010/01/12. doi:10.1371/journal. ppat.1000718. PubMed PMID: 20062797; PubMed Central PMCID: PMC2798752.
77. Pierson TC, Xu Q, Nelson S, Oliphant T, Nybakken GE, Fremont DH, et al. The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe. 2007;1(2):135-45. Epub 2007/11/17. doi: 10.1016/j.chom.2007.03.002. PubMed PMID: 18005691; Pub- Med Central PMCID: PMC2656919.
78. Krilov LR, Anderson LJ, Marcoux L, Bonagura VR, Wedgwood JF. Antibody-mediated enhancement of respiratory syncytial virus infection in two monocyte/macrophage cell lines. J Infect Dis. 1989;160(5):777-82. Epub 1989/11/01. PubMed PMID: 2809253.
79. Yao JS, Kariwa H, Takashima I, Yoshimatsu K, Arikawa J, Hashimoto N. Antibody-dependent enhancement of hantavirus infection in macrophage cell lines. Arch Virol. 1992;122(1-2): 107-18. Epub 1992/01/01. PubMed PMID: 1370367.
80. Takada A, Feldmann H, Ksiazek TG, Kawaoka Y. Antibodydependent enhancement of Ebola virus infection. J Virol. 2003;77(13):7539-44. Epub 2003/06/14. PubMed PMID: 12805454; PubMed Central PMCID: PMC164833.
81. Meyer K, Ait-Goughoulte M, Keck ZY, Foung S, Ray R. Antibody-dependent enhancement of hepatitis C virus infection. J Virol. 2008;82(5):2140-9. Epub 2007/12/21. doi:10.1128/JVI. 01867-07. PubMed PMID: 18094180; PubMed Central PMCID: PMC2258956.
82. Willey S, Aasa-Chapman MM, O'Farrell S, Pellegrino P, Williams I, Weiss RA, et al. Extensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infection. Retrovirology. 2011;8:16. Epub 2011/03/16. doi:10.1186/1742-4690-8-16. PubMed PMID: 21401915; PubMed Central PMCID: PMC3065417.
83. Gimenez HB, Chisholm S, Dornan J, Cash P. Neutralizing and enhancing activities of human respiratory syncytial virus-specific antibodies. Clin Diagn Lab Immunol. 1996;3(3):280-6. Epub 1996/05/01. PubMed PMID: 8705669; PubMed Central PMCID: PMC170331.
84. Lagging LM, Meyer K, Westin J, Wejstal R, Norkrans G, Lindh M, et al. Neutralization of pseudotyped vesicular stomatitis virus expressing hepatitis C virus envelope glycoprotein 1 or 2 by serum from patients. J Infect Dis. 2002;185(8): 1165-9. Epub 2002/04/04. doi:10.1086/339679. PubMed PMID: 11930327.
85. Rothman AL, Morishima C, Bonkovsky HL, Polyak SJ, Ray R, Di Bisceglie AM, et al. Associations among clinical, immunological, and viral quasispecies measurements in advanced chronic hepatitis C. Hepatology. 2005;41(3):617-25. Epub 2005/02/24. doi:10.1002/hep.20581. PubMed PMID: 15726656.
86. Morishima C, Polyak SJ, Ray R, Doherty MC, Di Bisceglie AM, Malet PF, et al. Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C. J Infect Dis. 2006;193(7):931-40. Epub 2006/03/07. doi:10.1086/500952. PubMed PMID: 16518754.
87. Ray R, Meyer K, Banerjee A, Basu A, Coates S, Abrignani S, et al. Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins. J Infect Dis. 2010; 202(6):862-6. Epub 2010/08/04. doi:10.1086/655902. PubMed PMID: 20677942; PubMed Central PMCID: PMC2931414.
88. Yu Q, Yu R, Qin X. The good and evil of complement activation in HIV-1 infection. Cell Mol Immunol. 2010;7(5):334-40. Epub 2010/03/17. doi:10.1038/cmi.2010.8. PubMed PMID: 20228834.
89. Gras GS, Dormont D. Antibody-dependent and antibody-independent complement-mediated enhancement of human immunodeficiency virus type 1 infection in a human, Epstein-Barr virus-transformed B-lymphocytic cell line. J Virol. 1991;65(1): 541-5. Epub 1991/01/01. PubMed PMID: 1845908; PubMed Central PMCID: PMC240554.
90. Srikiatkhachorn A. Plasma leakage in dengue haemorrhagic fever. Thromb Haemost. 2009;102(6):1042-9. Epub 2009/12/08. doi:10.1160/TH09-03-0208. PubMed PMID: 19967133.
91. Rothman AL. Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat Rev Immunol. 2011;11(8):532-43. Epub 2011/07/16. doi:10.1038/nri3014. PubMed PMID: 21760609.
92. Lin CF, Lei HY, Liu CC, Liu HS, Yeh TM, Wang ST, et al. Generation of IgM anti-platelet autoantibody in dengue patients. J Med Virol. 2001;63(2):143-9. Epub 2001/02/15. doi: 10.1002/1096-9071(20000201)63:2\143::AID-JMV1009[3.0. CO;2-L. PubMed PMID: 11170051.
93. Lin CF, Lei HY, Shiau AL, Liu CC, Liu HS, Yeh TM, et al. Antibodies from dengue patient sera cross-react with endothelial cells and induce damage. J Med Virol. 2003;69(1):82-90. Epub 2002/11/19. doi:10.1002/jmv.10261. PubMed PMID: 12436482.
94. Lin C. Autoimmunity in dengue virus infection. Dengue Bull. 2004;28:51-7.
95. Liu IJ, Chiu CY, Chen YC, Wu HC. Molecular mimicry of human endothelial cell antigen by autoantibodies to nonstructural protein 1 of dengue virus. J Biol Chem. 2011;286(11): 9726-36. Epub 2011/01/15. doi:10.1074/jbc.M110.170993. PubMed PMID: 21233208; PubMed Central PMCID: PMC3058979.
96. Misra A, Mukerjee R, Chaturvedi UC. Production of nitrite by dengue virus-induced cytotoxic factor. Clin Exp Immunol. 1996;104(3):406-11. Epub 1996/06/01. PubMed PMID: 90999 23; PubMed Central PMCID: PMC2200459.
97. Lin YS, Yeh TM, Lin CF, Wan SW, Chuang YC, Hsu TK, et al. Molecular mimicry between virus and host and its implications for dengue disease pathogenesis. Exp Biol Med (Maywood). 2011;236(5):515-23. Epub 2011/04/20. doi:10.1258/ebm.2011.010339. PubMed PMID: 21502191.
98. Markoff LJ, Innis BL, Houghten R, Henchal LS. Development of cross-reactive antibodies to plasminogen during the immune response to dengue virus infection. J Infect Dis. 1991;164(2): 294-301. Epub 1991/08/01. PubMed PMID: 1856477.
99. Chungue E, Poli L, Roche C, Gestas P, Glaziou P, Markoff LJ. Correlation between detection of plasminogen cross-reactive antibodies and hemorrhage in dengue virus infection. J Infect Dis. 1994;170(5):1304-7. Epub 1994/11/01. PubMed PMID: 7963733.
100. Huang YH, Chang BI, Lei HY, Liu HS, Liu CC, Wu HL, et al. Antibodies against dengue virus E protein peptide bind to human plasminogen and inhibit plasmin activity. Clin Exp Immunol. 1997;110(1):35-40. Epub 1997/11/14. PubMed PMID: 9353146; PubMed Central PMCID: PMC1904795.
101. Bettaieb. Cross-reactive antibodies between HIV-gp120 and platelet gpIIIa (CD61) in HIV-related immune thrombocytopenic purpura. Clin Exp Immunol. 1996;103(1):19-23.
102. Zhang W, Nardi MA, Borkowsky W, Li Z, Karpatkin S. Role of molecular mimicry of hepatitis C virus protein with platelet GPIIIa in hepatitis C-related immunologic thrombocytopenia. Blood. 2009;113(17):4086-93. Epub 2008/11/22. doi: 10.1182/blood-2008-09-181073. PubMed PMID: 19023115; PubMed Central PMCID: PMC2673130.
103. Marceau G, Lapierre P, Beland K, Soudeyns H, Alvarez F. LKM1 autoantibodies in chronic hepatitis C infection: a case of molecular mimicry? Hepatology. 2005;42(3):675-82. Epub 2005/07/23. doi:10.1002/hep.20816. PubMed PMID: 16037945.
104. Sansonno D, Tucci FA, Ghebrehiwet B, Lauletta G, Peerschke EI, Conteduca V, et al. Role of the receptor for the globular domain of C1q protein in the pathogenesis of hepatitis C virusrelated cryoglobulin vascular damage. J Immunol. 2009;183(9):6013-20. Epub 2009/10/16. doi:10.4049/jimmunol.0902038. PubMed PMID: 19828637; PubMed Central PMCID: PMC2794553.
105. Crowson AN, Magro CM. Recent advances in the pathology of cutaneous drug eruptions. Dermatologic clinics. 1999;17(3): 537-60, viii. Epub 1999/07/20. PubMed PMID: 10410857.
106. Nocente R, Ceccanti M, Bertazzoni G, Cammarota G, Silveri NG, Gasbarrini G. HCV infection and extrahepatic manifestations. Hepato-gastroenterology. 2003;50(52):1149-54. Epub 2003/07/09. PubMed PMID: 12846002.
107. Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology. 2005;42(4):962-73. Epub 2005/09/09. doi:10.1002/hep. 20819. PubMed PMID: 16149085.
108. Hay AJ, Gregory V, Douglas AR, Lin YP. The evolution of human influenza viruses. Philosophical transactions of the Royal Society of London Series B, Biological sciences. 2001; 356(1416):1861-70. Epub 2002/01/10. doi:10.1098/rstb.2001.0999. PubMed PMID: 11779385; PubMed Central PMCID: PMC1088562.
109. Wu X, Zhou T, Zhu J, Zhang B, Georgiev I, Wang C, et al. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science. 2011;333(6049):1593-602. Epub 2011/08/13. doi:10.1126/science.1207532. PubMed PMID: 21835983.
110. Ekiert DC, Friesen RH, Bhabha G, Kwaks T, Jongeneelen M, Yu W, et al. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science. 2011;333(6044):843-50. Epub 2011/07/09. doi:10.1126/science.1204839. PubMed PMID: 21737702; PubMed Central PMCID: PMC3210727.
111. Ichiyoshi Y, Zhou M, Casali P. A human anti-insulin IgG autoantibody apparently arises through clonal selection from an insulin-specific "germ-line" natural antibody template. Analysis by V gene segment reassortment and site-directed mutagenesis. J Immunol. 1995;154(1):226-38. Epub 1995/01/01. PubMed PMID: 7995943.
112. Martin T, Crouzier R, Weber JC, Kipps TJ, Pasquali JL. Structure-function studies on a polyreactive (natural) autoantibody. Polyreactivity is dependent on somatically generated sequences in the third complementarity-determining region of the antibody heavy chain. J Immunol. 1994;152(12):5988-96. Epub 1994/06/15. PubMed PMID: 8207223.
113. Haynes BF, Fleming J, St Clair EW, Katinger H, Stiegler G, Kunert R, et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science. 2005; 308(5730):1906-8. Epub 2005/04/30. doi:10.1126/science.1111781. PubMed PMID: 15860590.
114. Morris L, Chen X, Alam M, Tomaras G, Zhang R, Marshall DJ, et al. Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting. PLoS One. 2011;6(9):e23532. Epub 2011/10/08. doi: 10.1371/journal.pone.0023532. PubMed PMID: 21980336; PubMed Central PMCID: PMC3184076.
115. Mouquet H, Klein F, Scheid JF, Warncke M, Pietzsch J, Oliveira TY, et al. Memory B cell antibodies to HIV-1 gp140 cloned from individuals infected with clade A and B viruses. PLoS One. 2011;6(9):e24078. Epub 2011/09/21. doi:10.1371/journal.pone.0024078. PubMed PMID: 21931643; PubMed Central PMCID: PMC3169578.
116. Scheid JF, Mouquet H, Feldhahn N, Seaman MS, Velinzon K, Pietzsch J, et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature. 2009;458(7238):636-40. Epub 2009/03/17. doi:10.1038/ nature07930. PubMed PMID: 19287373.
117. Harindranath N, Ikematsu H, Notkins AL, Casali P. Structure of the VH and VL segments of polyreactive and monoreactive human natural antibodies to HIV-1 and Escherichia coli betagalactosidase. International immunology. 1993;5(12):1523-33. Epub 1993/12/01. PubMed PMID: 8312222.
118. Warsame AA, Aasheim HC, Nustad K, Troen G, Tierens A, Wang V, et al. Splenic marginal zone lymphoma with VH1-02 gene rearrangement expresses poly-
119. Ekiert DC, Bhabha G, Elsliger MA, Friesen RH, Jongeneelen M, Throsby M, et al. Antibody recognition of a highly conserved influenza virus epitope. Science. 2009;324(5924):246-51. Epub 2009/03/03. doi:10.1126/science.1171491. PubMed PMID: 19251591; PubMed Central PMCID: PMC2758658.
120. Throsby M, van den Brink E, Jongeneelen M, Poon LL, Alard P, Cornelissen L, et al. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM? memory B cells. PloS one. 2008;3(12): e3942. Epub 2008/12/17. doi:10.1371/journal.pone.0003942. PubMed PMID: 19079604; PubMed Central PMCID: PMC2596486.
121. Chan CH, Hadlock KG, Foung SK, Levy S. V(H)1-69 gene is preferentially used by hepatitis C virus-associated B cell lymphomas and by normal B cells responding to the E2 viral antigen. Blood. 2001;97(4):1023-6. Epub 2001/02/13. PubMed PMID: 11159532.
122. Ivanovski M, Silvestri F, Pozzato G, Anand S, Mazzaro C, Burrone OR, et al. Somatic hypermutation, clonal diversity, and preferential expression of the VH 51p1/VL kv325 immunoglobulin gene combination in hepatitis C virus-associated immunocytomas. Blood. 1998;91(7):2433-42. Epub 1998/04/18. PubMed PMID: 9516143.
123. Craig VJ, Arnold I, Gerke C, Huynh MQ, Wundisch T, Neubauer A, et al. Gastric MALT lymphoma B cells express polyreactive, somatically mutated immunoglobulins. Blood. 2010;115(3):581-91. Epub 2009/12/08. doi:10.1182/blood- 2009-06-228015. PubMed PMID: 19965661.
124. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn S, et al. Dengue in the early febrile phase: viremia and antibody responses. J Infect Dis. 1997; 176(2):322-30. PubMed PMID: 9237696.
125. Wrammert J, Koutsonanos D, Li GM, Edupuganti S, Sui J, Morrissey M, et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med. 2011;208(1):181-93. Epub 2011/01/12. doi:10.1084/jem.20101352. PubMed PMID: 21220454; PubMed Central PMCID: PMC3023136.
126. Galli G, Hancock K, Hoschler K, DeVos J, Praus M, Bardelli M, et al. Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc Natl Acad Sci USA. 2009;106(19):7962-7. Epub 2009/05/07. doi:10.1073/pnas.0903181106. PubMed PMID: 19416838; PubMed Central PMCID: PMC2674105.